16 research outputs found
Identification of 8‑Aminoadenosine Derivatives as a New Class of Human Concentrative Nucleoside Transporter 2 Inhibitors
Purine-rich foods have long been
suspected as a major cause of
hyperuricemia. We hypothesized that inhibition of human concentrative
nucleoside transporter 2 (hCNT2) would suppress increases in serum
urate levels derived from dietary purines. To test this hypothesis,
the development of potent hCNT2 inhibitors was required. By modifying
adenosine, an hCNT2 substrate, we successfully identified 8-aminoadenosine
derivatives as a new class of hCNT2 inhibitors. Compound <b>12</b> moderately inhibited hCNT2 (IC<sub>50</sub> = 52 ± 3.8 μM),
and subsequent structure–activity relationship studies led
to the discovery of compound <b>48</b> (IC<sub>50</sub> = 0.64
± 0.19 μM). Here we describe significant findings about
structural requirements of 8-aminoadenosine derivatives for exhibiting
potent hCNT2 inhibitory activity
Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo
1. First developed as an antiallergic drug, tranilast inhibits chemical mediator release from mast cells. In the present study, we examine the effects of tranilast on angiogenesis in vitro and in vivo and discuss the application of tranilast for angiogenic diseases. 2. Tranilast inhibited significantly the proliferation (IC(50): 136 μM, 95% confidence limits: 124–137 μM) and vascular endothelium growth factor (VEGF)-induced chemotaxis (IC(50): 135 μM, 95% confidence limits: 124–147 μM) of human dermal microvascular endothelial cells (HDMECs) at concentrations greater than 25 μg ml(−1). No toxicity to HDMECs measuring by LDH release and no inhibitory effects on metalloproteinase (MMP)-2 and MMP-9 activity were observed even at 100 μg ml(−1) (306 μM). 3. Tube formation of HDMECs cultured on the matrigel as an in vitro angiogenesis model was inhibited by tranilast in a concentration-dependent manner. The IC(50) value and 95% confidence limits were 175 μM and 151–204 μM, respectively. 4. In vivo angiogenesis was induced in mice by the subcutaneous injection of matrigel containing 30 ng ml(−1) VEGF and 64 μg ml(−1) heparin. Tranilast was administered orally twice a day for 3 days. Tranilast dose-dependently suppressed angiogenesis in the matrigel and a significant change was observed at a dose of 300 mg kg(−1). 5. These results indicate that tranilast is an angiogenesis inhibitor which may be beneficial for the improvement of angiogenic diseases such as proliferative diabetic retinopathy, age-related macular degeneration, tumour invasion and rheumatoid arthritis
Identification of Adenine and Benzimidazole Nucleosides as Potent Human Concentrative Nucleoside Transporter 2 Inhibitors: Potential Treatment for Hyperuricemia and Gout
To test the hypothesis that inhibitors
of human concentrative nucleoside
transporter 2 (hCNT2) suppress increases in serum urate levels derived
from dietary purines, we previously identified adenosine derivative <b>1</b> as a potent hCNT2 inhibitor (IC<sub>50</sub> = 0.64 μM),
but further study was hampered due to its poor solubility. Here we
describe the results of subsequent research to identify more soluble
and more potent hCNT2 inhibitors, leading to the discovery of the
benzimidazole nucleoside <b>22</b>, which is the most potent
hCNT2 inhibitor (IC<sub>50</sub> = 0.062 μM) reported to date.
Compound <b>22</b> significantly suppressed the increase in
plasma uric acid levels after oral administration of purine nucleosides
in rats. Because compound <b>22</b> was poorly absorbed orally
in rats (<i>F</i> = 0.51%), its pharmacologic action was
mostly limited to the gastrointestinal tract. These findings suggest
that inhibition of hCNT2 in the gastrointestinal tract can be a promising
approach for the treatment of hyperuricemia
Identification of Adenine and Benzimidazole Nucleosides as Potent Human Concentrative Nucleoside Transporter 2 Inhibitors: Potential Treatment for Hyperuricemia and Gout
To test the hypothesis that inhibitors
of human concentrative nucleoside
transporter 2 (hCNT2) suppress increases in serum urate levels derived
from dietary purines, we previously identified adenosine derivative <b>1</b> as a potent hCNT2 inhibitor (IC<sub>50</sub> = 0.64 μM),
but further study was hampered due to its poor solubility. Here we
describe the results of subsequent research to identify more soluble
and more potent hCNT2 inhibitors, leading to the discovery of the
benzimidazole nucleoside <b>22</b>, which is the most potent
hCNT2 inhibitor (IC<sub>50</sub> = 0.062 μM) reported to date.
Compound <b>22</b> significantly suppressed the increase in
plasma uric acid levels after oral administration of purine nucleosides
in rats. Because compound <b>22</b> was poorly absorbed orally
in rats (<i>F</i> = 0.51%), its pharmacologic action was
mostly limited to the gastrointestinal tract. These findings suggest
that inhibition of hCNT2 in the gastrointestinal tract can be a promising
approach for the treatment of hyperuricemia
International consensus guidelines on the role of diagnostic endoscopic ultrasound in the management of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club.
BackgroundChronic pancreatitis (CP) is a complex inflammatory disease with variable presentations and outcomes. This statement is part of the international consensus guidelines on CP, specifically on the diagnostic role of endoscopic ultrasound (EUS).MethodsAn international working group with experts on the role of diagnostic EUS in the management of CP from the major pancreas societies (IAP, APA, JPS, and EPC) evaluated two key statements generated from evidence on two questions deemed to be the most clinically relevant. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to evaluate the level of evidence available for each statement. To determine the level of agreement, the working group voted on each statement for strength of agreement, using a nine-point Likert scale in order to calculate Cronbach's alpha reliability coefficient.ResultsStrong consensus was obtained for both of the following statements [1]. The ideal threshold number of EUS criteria necessary to diagnose CP has not been firmly established, but the presence of 5 or more and 2 or less strongly suggests or refutes the diagnosis, respectively. The Rosemont scoring system standardizes the reporting of EUS signs indicative of chronic pancreatitis, but further studies are needed to demonstrate an overall improvement of its diagnostic accuracy over conventional scoring [2]. Specificity, inter- and intra-observer variability and pre-test probability limit the reliability and utility of EUS to help diagnose CP especially early stages of the disease.ConclusionsThe presence of 5 or more and 2 or less EUS criteria strongly suggests or refutes the diagnosis of CP, respectively. Intra-observer variability still limits the role of EUS in diagnosing CP especially early stage disease
New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS)
The symposium “New criteria of resectability for pancreatic cancer” was held during the 33nd meeting of the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS) in 2021 to discuss the potential modifications that could be made in the current resectability classification. The meeting focused on setting the foundation for developing a new prognosis-based resectability classification that is based on the tumor biology and the response to neoadjuvant treatment (NAT). The symposium included selected experts from Western and Eastern high-volume centers who have discussed their concept of resectability status through published literature. During the symposium, presenters reported new resectability classifications from their respective institutions based on tumor biology, conditional status, pathology, and genetics, in addition to anatomical tumor involvement. Interestingly, experts from all the centers reached the agreement that anatomy alone is insufficient to define resectability in the current era of effective NAT. On behalf of the JSHBPS, we would like to summarize the content of the conference in this position paper. We also invite global experts as internal reviewers of this paper for intercontinental cooperation in creating an up-to-date, prognosis-based resectability classification that reflects the trends of contemporary clinical practice
International consensus guidelines on interventional endoscopy in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club
Background/objectives: This paper is part of the international consensus guidelines on chronic pancreatitis, presenting for interventional endoscopy. Methods: An international working group with experts on interventional endoscopy evaluated 26 statements generated from evidence on 9 clinically relevant questions. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to evaluate the level of evidence. To determine the level of agreement, a nine-point Likert scale was used for voting on the statements. Results: Strong consensus was obtained for 15 statements relating to nine questions including the recommendation that endoscopic intervention should be offered to patients with persistent severe pain but not to those without pain. Endoscopic decompression of the pancreatic duct could be used for immediate pain relief, and then offered surgery if this fails or needs repeated endoscopy. Endoscopic drainage is preferred for portal-splenic vein thrombosis and pancreatic fistula. A plastic stent should be placed and replaced 2–3 months later after insertion. Endoscopic extraction is indicated for stone fragments remaining after ESWL. Interventional treatment should be performed for symptomatic/complicated pancreatic pseudocysts. Endoscopic treatment is recommended for bile duct obstruction and afterwards surgery if this fails or needs repeated endoscopy. Surgery may be offered if there is significant calcification and/or mass of the pancreatic head. Percutaneous endovascular treatment is preferred for hemosuccus pancreaticus. Surgical treatment is recommended for duodenal stenosis due to chronic pancreatitis. Conclusions: This international expert consensus guideline provides evidenced-based statements concerning indications and key aspects for interventional endoscopy in the management of patients with chronic pancreatitis